Paclitaxel, the first of the taxanes, has exhibited unique andencouraging single-agent
activity in the treatment of non-small celllung cancer (NSCLC). Yet, with single-agent
response rates approaching25%, it was logical to examine the impact of paclitaxel in
combinationchemotherapy regimens. In trials evaluating the activity of paclitaxelin
combination with one of the platinum compounds, cisplatin orcarboplatin, response rates
have ranged from 35 to> 50% and weresignificantly better than response rates observed …